1.Regulation of cyclosporin A on nm23-H1 expression in human trophoblast
Xiaofan HOU ; Keming XIE ; Mingqing LI ; Dajin LI
Chinese Journal of Pathophysiology 1986;0(03):-
AIM:To explore whether cyclosporine A (CsA) can regulate the expression of nometastatic gene23 H1 type (nm23-H1) in human choriocarcinoma Bewo cells,in order to seek new proof of treating trophoblast diseases.METHODS:The Bewo cells were divided into two groups. The vehicle control group,and the CsA group with different concentrations from 10-2 ?mol/L to 10 ?mol/L. The effect of CsA on the transcription of nm23-H1 was determined by reverse transcription-polymerase chain reaction (RT-PCR) after cultured for 48 h and protein level of nm23-H1 was determined by In-cell Western after cultured for 72 h.RESULTS:Compared to the vehicle group,CsA significantly downregulated the transcription and translation of nm23-H1 in a dose-dependent manner from 10-2 ?mol/L to 10 ?mol/L,and the inhibition reached its top when concentration of CsA was 1.0 ?mol/L (P
2.Aflatoxin M1 preparation and identification of artificial antigens
Qichao CAI ; Yuze HOU ; Ruiguang DENG ; Xiaofei HU ; Yao WANG ; Xiaofan ZHANG ; Fangyu WANG
Chinese Journal of Immunology 2014;(6):789-793
Objective:AFM1-BSA and AFM1-OVA were synthesized and then identified in this experiment.Methods: Using oximation method ,AFM1 was transformed to oxime compounds while the reaction process was monitored via TLC method aiming to identify the compounds.Coupled with carrier protein BSA and OVA respectively , we obtained AFM1-BSA and AFM1-OVA, then identified synthetic antigen via UV spectrophotometry and SDS-PAGE.Antigens were injected into experimental animals , finally obtaining the murine multi-antiserum.Eventually , the multi-antiserums were detected via indirect inhibition ELISA method to judge whether the antigens were effectively or not.Results:After oximation reaction ,the migration distance of oxime compounds in the thin layer plate was shorter.The maximum absorption peak of AFM1-BSA occurred in 274 nm,and was inconsistent with both UV absorption peaks of BSA and AFM 1.The electrophoretic velocity of AFM 1-BSA was less than that of BSA.All the titers of three immunized mice were 1×10-4 approximately;the multi-antiserum from No.3 sample had the best sensitivity ,its IC50 was 359.9 ng/ml.Conclusion:In this study,we obtained AFM1 artificial antigen and murine multi-antiserum of high sensitivity.
3.Antioxidant effect of persimmon leaf extract to HEK293-APPswe transgenic cells and effect to Nrf2/HO-1 pathway
Xiaofan WU ; Bin MA ; Xunyao HOU ; Yan HONG ; Chao SHEN ; Xueping LIU
Chinese Journal of Immunology 2017;33(6):854-858
Objective:To investigate the effect of persimmon leaf extract (PLE) on HEK293-APPswe transgenic cells (20E2).Methods:To determine whether the 20E2 cells model was successfully established,the level of Aβ1-40 in SH-SY5Y was detected and 20E2 cells(HEK293 cells stably expressing Swedish mutant APP)cultured in vivo by ELISA kit,and the expression of APP protein level was detected by Western blot.Cell viability was assayed by CCK-8 method and then selected the best concentration.Set groups:SH-SY5Y as normal control group (NC group),20E2 as model group (20E2 group),treating with PLE as treating group (20E2+PLE group).Reactive oxygen species (ROS) levels of each group were detected with DCFH-DA fluorescent probe.The extracellular level of Aβ1-42 were detected by ELISA kit.Cytoplasmic Nrf2,Nuclear Nri2,Whole-cell HO-1 were detected by Western blot.Results:Compared with model group,the expressions of ROS,Aβ1-42 were down-regulated and the Nuclear Nrf2 and Whole-cell HO-1 were up-regulated in 20E2+PLE group.Conclusion:PLE can reduce the level of oxidative stress of model group effectively,it possibly reduce the aggregation of Aβ1-42 and prevent oxidizing via activating Nrf2/HO-1 pathway.
4.Analysis of genome copy number variations in fetuses with isolated ventricular septal defect and a literature review.
Panlai SHI ; Yaqin HOU ; Duo CHEN ; Yanjie XIA ; Xiaofan ZHU ; Gege SUN ; Qianqian LI ; Mingcong SHE ; Xiangdong KONG
Chinese Journal of Medical Genetics 2023;40(3):317-321
OBJECTIVE:
To assess the value of copy number variation sequencing (CNV-seq) for revealing the genetic etiology of fetuses with isolated ventricular septal defect (VSD).
METHODS:
From December 2017 to December 2020, 69 fetuses with isolated VSD were identified at the First Affiliated Hospital of Zhengzhou University. Meanwhile, 839 similar prenatal cases were selected from public databases including Wanfang data, Wanfang Medicine, and China National Knowledge Infrastructure (CNKI) by using keywords such as "Ventricular septal defect", "Copy number variation", and "Prenatal". A total of 908 fetuses with isolated VSD were analyzed. CNV-seq was carried out for 69 fetuses.
RESULTS:
Among the 908 fetuses, 33 (3.63%) were found to harbor pathogenic CNVs, which included 11 chromosomal aneuploidies (1.21%) and 22 pathogenic CNVs (2.42%). The pathogenic CNVs have involved 12 genetic syndromes, with those known to involve the heart development including 5 cases of 22q11.21 deletion syndrome, 2 cases of 4q terminal deletion syndrome, and 1 case of 9q subtelomere deletion syndrome. The outcome of pregnancies for 15 fetuses with pathogenic CNVs was known, of which 12 were terminated, and 3 had spontaneous closure of the ventricular septum after birth, but 1 of them had other abnormalities.
CONCLUSION
Fetuses with isolated VSD have a relatively high risk for chromosomal abnormalities, for which CNV-seq should be recommended.
Female
;
Pregnancy
;
Humans
;
DNA Copy Number Variations
;
Heart Septal Defects, Ventricular/genetics*
;
22q11 Deletion Syndrome
;
Fetus
5.Role of transforming growth factor-β in the development and progression of pancreatic cancer
Hao ZHANG ; Linxun LIU ; Zhanxue ZHAO ; Hongshuai PAN ; Xiaofan HOU ; Zheng HUO
Journal of Clinical Hepatology 2022;38(12):2892-2896
Pancreatic ductal adenocarcinoma has a high degree of malignancy, an insidious onset, and rapid progression, with no obvious abdominal manifestations and signs in the early stage. Most patients are already in the advanced stage and have distant organ metastasis at the time of diagnosis, and thus surgical treatment, chemoradiotherapy, and targeted drug therapy often have an unsatisfactory clinical effect. Recent studies have shown that transforming growth factor-β (TGF-β) is closely associated with the development and of tumors and plays a key role in the processes of tumor cell proliferation, invasion, migration, and angiogenesis. Although TGF-β signal can exert a powerful inhibitory effect on tumors through SMAD-mediated cell cycle arrest, TGF-β signal can also accelerate the development of pancreatic cancer by enhancing epithelial-mesenchymal transition, fibrosis, and immune escape. In this article, pancreatic cancer specifically refers to pancreatic ductal adenocarcinoma, and this article reviews the role of TGF-β in its signal transduction and the association of TGF-β with related factors and immune response, so as to provide a theoretical basis for targeted therapy for pancreatic cancer in the future.
6.Role of thymoquinone in treatment of pancreatic cancer
Zhanxue ZHAO ; Linxun LIU ; Shuai LI ; Xiaofan HOU ; Jinyu YANG
Journal of Clinical Hepatology 2023;39(5):1234-1244
Pancreatic cancer is one of the cancers with the worst prognosis, and its high metastasis rate and resistance to chemotherapy drugs have always been the tough problems in the medical field. At present, the effect of thymoquinone on pancreatic cancer has attracted wide attention, and it can exert an antitumor effect in pancreatic cancer by inhibiting cancer cell proliferation, promoting cancer cell apoptosis, inhibiting invasion and metastasis, enhancing the sensitivity to chemotherapy drugs, and exerting an anti-inflammatory effect. This review briefly introduces the current research status of the association between thymoquinone and pancreatic cancer in China and globally, so as to provide a reference for subsequent research.
7. A prospective study of the efficacy and safety of maintenance therapy with recombinant human thrombopoietin in patients with primary immune thrombocytopenia: a multicenter study
Huacong CAI ; Shujie WANG ; Ling FU ; Xiaomin WANG ; Ming HOU ; Ping QIN ; Fangping CHEN ; Xiaohui ZHANG ; He HUANG ; Jingsong HE ; Runhui WU ; Jingyao MA ; Renchi YANG ; Xiaofan LIU ; Ying TIAN ; Aijun LIU ; Jingsheng WU ; Weibo ZHU ; Yuhong ZHOU ; Wenbin LIU ; Yu HU ; Wenjuan HE ; Yan LI ; Deng PAN ; Yongqiang ZHAO
Chinese Journal of Hematology 2017;38(5):379-383
Objective:
To evaluate the efficacy and safety of maintenance therapy with reduced dose of rhTPO in the patients with primary immune thrombocytopenia (ITP) who attained stable platelet (PLT) counts after daily administration of rhTPO.
Methods:
Treatment was started with a daily administration of rhTPO (300 U/kg) for 2 consecutive weeks. Patients who attained stable PLT≥50×109/L were enrolled to maintenance therapy starting with every other day administration of rhTPO, then adjusted dose interval to maintain platelet count (30-100) ×109/L.
Results:
A total of 91 eligible patients were enrolled. Fourteen patients discontinued the study due to noncompliance (12/14) and investigator decision (2/14) . Among 77 patients who completed the study, 38 patients with the administration of rhTPO at every other day or less could maintain PLT≥30×109/L for 12 weeks. The percentage of patients with a platelet response (PLT≥30×109/L) at 4th week, 8th week and 12th week of maintain therapy was 92.6% (63/68) , 82.7% (43/52) and 85.0% (34/40) , respectively. Median platelet counts remained in the range of (70-124) ×109/L. The overall incidence of rhTPO-related adverse events was 7.7%. All the adverse events were generally mild.
Conclusion
Extending the dose interval of rhTPO is feasible to maintain stable platelet count in the patients with ITP, but the optimal dose interval is uncertain and might vary with individuals.